Esperion Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprot...
Key facts: Esperion to Delist from Nasdaq; Merger Creates $100M CVR
Esperion acquired in cash-and-CVR merger transaction
Archimed completes take-private of Esperion in deal valued up to $1.1 billion
Esperion Therapeutics Closes Merger; Sets $100M CVR Plan, Amends 2030 Notes, Replaces Credit Facility
Esperion directors Justin Bateman and Ankit Pareek elected as six incumbent directors depart
Esperion Therapeutics Announced Transfer or Voluntary Withdrawal of Listing